A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 5, 2011, Pages 636-647

  Chiba, Toshiki ^a   Ueno, Sanae ^a   Obara, Yutaro ^a   Nakahata, Norimichi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

cannabinoid; cerebellar granule cells; CP55940; cytokine; inflammation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CALCIUM ION; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYTOKINE; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NESS 0327; PHOSPHATIDYLINOSITIDE; PROTEIN GPR55; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; GRANULE CELL; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; CALCIUM; CANNABIDIOL; CANNABINOIDS; CEREBELLUM; CYCLOHEXANOLS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; GLYCERIDES; INFLAMMATION; LIPOPOLYSACCHARIDES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79954752203     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01250.x     Document Type: Article

References (48)

1. Di Marzo V, et al,. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784. (Pubitemid 39242829)
2. Howlett AC, et al,. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
3. Devane WA, et al,. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949. (Pubitemid 23026736)
4. Sugiura T, et al,. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
5. Mechoulam R, et al,. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
6. Matsuda LA, et al,. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
7. Munro S, et al,. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65. (Pubitemid 23305569)
8. Pertwee RG,. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180. (Pubitemid 27337346)
9. Wiley JL, et al,. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 1995; 34: 669-676.
10. Centonze D, et al,. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007; 28: 180-187. (Pubitemid 46483718)
11. Ryberg E, et al,. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101. (Pubitemid 350166046)
12. Baker D, et al,. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27: 1-4. (Pubitemid 43063115)
13. Lauckner JE, et al,. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-2704. (Pubitemid 351520576)
14. Oka S, et al,. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007; 362: 928-934. (Pubitemid 47390663)
15. Henstridge CM, et al,. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 2009; 23: 183-193.
16. Kapur A, et al,. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 2009; 284: 29817-29827.
17. Begg M, et al,. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-145. (Pubitemid 40613055)
18. Watkins LR, et al,. Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci 1995; 57: 1011-1026.
19. Lucas SM, et al,. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147 (Suppl. 1): S232-S240.
20. Facchinetti F, et al,. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003; 41: 161-168. (Pubitemid 36262193)
21. Molina-Holgado F, et al,. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002; 67: 829-836. (Pubitemid 34226296)
22. Puffenbarger RA, et al,. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29: 58-69. (Pubitemid 30031134)
23. Molina-Holgado F, et al,. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998; 433: 139-142. (Pubitemid 28386745)
24. Molina-Holgado F, et al,. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003; 23: 6470-6474. (Pubitemid 36909872)
25. Roche M, et al,. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 2006; 181: 57-67. (Pubitemid 44827290)
26. Roth MD, et al,. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002; 121: 229-239. (Pubitemid 36044554)
27. Waksman Y, et al,. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999; 288: 1357-1366. (Pubitemid 29254178)
28. Schwarz H, et al,. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994; 55: 107-115. (Pubitemid 24356812)
29. Jeon YJ, et al,. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 1996; 50: 334-341. (Pubitemid 26265138)
30. Obara Y, et al,. The requirement of Ras and Rap1 for the activation of ERKs by cAMP, PACAP, and KCl in cerebellar granule cells. J Neurochem 2007; 101: 470-482. (Pubitemid 46525282)
31. Nakahata N, et al,. Thromboxane A2 activates phospholipase C in astrocytoma cells via pertussis toxin-insensitive G-protein. Eur J Pharmacol 1989; 162: 407-417. (Pubitemid 19091068)
32. Gkoumassi E, et al,. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br J Pharmacol 2007; 151: 1041-1048. (Pubitemid 47195535)
33. Stoit AR, et al,. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull (Tokyo) 2002; 50: 1109-1113. (Pubitemid 41702075)
34. Zhang Y, et al,. Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole- 3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations. J Med Chem 2008; 51: 3526-3539. (Pubitemid 351875008)
35. Sawzdargo M, et al,. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999; 64: 193-198. (Pubitemid 29052470)
36. Gloire G, et al,. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72: 1493-1505. (Pubitemid 44666727)
37. Hampson AJ, et al,. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-8273. (Pubitemid 28326102)
38. Kraft B, et al,. Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. Life Sci 2004; 75: 969-977. (Pubitemid 38749256)
39. Galiegue S, et al,. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
40. Bisogno T, et al,. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 1997; 322 (Pt 2): 671-677. (Pubitemid 27116599)
41. Oka S, et al,. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. Eur J Pharmacol 2006; 538: 154-162.
42. Pacheco M, et al,. Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 1991; 257: 170-183.
43. Pacheco MA, et al,. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 1993; 603: 102-110. (Pubitemid 23065877)
44. Ross RA,. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003; 140: 790-801. (Pubitemid 37464060)
45. Pertwee RG,. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006; 30 (Suppl. 1): S13-S18.
46. Nakajima Y, et al,. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett 2006; 580: 613-619. (Pubitemid 43089695)
47. Oliveira-Marques V, et al,. Role of hydrogen peroxide in NF-kappaB activation: from inducer to modulator. Antioxid Redox Signal 2009; 11: 2223-2243.
48. Oesch S, Gertsch J,. Cannabinoid receptor ligands as potential anticancer agents-high hopes for new therapies? J Pharm Pharmacol 2009; 61: 839-853.